Syngenta will stop selling paraquat in Australia due to new regulations making it commercially unviable, despite the Australian Pesticides and Veterinary Medicines Authority (APVMA) finding no increased Parkinson’s disease risk from approved uses. The decision follows June's restrictions to mitigate acute exposure and animal risks.
A large Danish study of 3.1 million participants over 18 years found a modest but consistent association between long-term exposure to road traffic noise and a 3% higher risk of Parkinson’s disease for every 11.5dB rise in noise. Having a quiet part of the home may mitigate this risk.
Chinese company Nuwacell claims its stem cell therapy for Parkinson's disease shows significantly higher efficiency (80-90% conversion) than international competitors (below 25%), citing faster clinical trial timelines.
UCL researchers discovered signature changes in gut microbiome that identify people at greater risk of Parkinson's disease before symptoms develop. The study found 176 gut microbe species differed in Parkinson's patients, with similar changes in those with genetic risk but no symptoms. The findings raise hopes for dietary interventions and treatments that reshape the microbiome to prevent or delay the disease.
Chinese biomedical companies deploying cutting-edge technologies are emerging as serious competitors to Western dominance in the race to treat Parkinson’s disease, in a market that could reach US$16 billion over the next decade. The firms are developing a range of approaches – from autologous cell therapies made from a patient’s own cells and ready-made cell products to gene therapies and non-invasive ultrasounds – although many of these candidates are still in early-stage trials. Many patients...
